{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:29:29Z","timestamp":1790882969209,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite the proven efficacy of medications for opioid use disorder (MOUD) and recent reduction in barriers to prescribers, numerous obstacles exist for patients seeking MOUD. Prior studies have used telephone surveys to investigate pharmacy-related barriers to MOUD. We applied this methodology to evaluate inpatient and outpatient pharmacy barriers to MOUD in South Florida.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Randomly selected pharmacies in South Florida (Miami-Dade, Broward, and Palm Beach Counties) were called using a standardized script with a \u201csecret shopper\u201d approach until 200 successful surveys had been completed. The primary outcome was the availability of any buprenorphine products. Second, a list of all 48 acute care hospitals within the aforementioned counties was compiled, and hospitals were contacted by telephone using a second structured script.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1374 outpatient pharmacies and 48 inpatient pharmacies were identified. 378 randomly selected outpatient pharmacies were contacted to accrue 200 successful calls (53% success rate). All 48 inpatient pharmacies were contacted to successfully complete 25 inpatient surveys (52%). Of the 200 outpatient pharmacies contacted, 38% had any buprenorphine available. There was a significant difference in buprenorphine availability by county, with Miami-Dade having the least availability and Palm Beach having the most availability (27% vs. 47%, respectively; p\u2009=\u20090.04). Of the 38% with buprenorphine available, 82% had a sufficient supply for a two-week prescription of buprenorphine 8\u00a0mg twice daily. Of the pharmacies that did not have buprenorphine, 55% would be willing to order with a median estimated time to receive an order of 2\u00a0days (IQR 1.25\u20133\u00a0days). Of the 25 surveyed inpatient pharmacies, 88% reported having buprenorphine on inpatient formulary, and 55% of hospitals had at least one restriction on ordering of buprenorphine beyond federal regulations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results of this study highlight significant pharmacy-related barriers to comprehensive OUD treatment across the healthcare system including both acute care hospital pharmacies and outpatient community pharmacies. Despite efforts to increase the number of MOUD providers, there still remain downstream obstacles to MOUD access.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-022-00346-x","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T09:51:09Z","timestamp":1668765069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Availability of medications for opioid use disorder in outpatient and inpatient pharmacies in South Florida: a secret shopper survey"],"prefix":"10.1186","volume":"17","author":[{"given":"Alina","family":"Syros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Rennick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace A.","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Gibstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"de la Parte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Hermenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina J.","family":"Ciraldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa A.","family":"Chueng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansel E.","family":"Tookes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler S.","family":"Bartholomew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8505-6617","authenticated-orcid":false,"given":"David P.","family":"Serota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"346_CR1","unstructured":"NVSS vital statistics rapid release: provisional drug overdose death counts 2022. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm."},{"key":"346_CR2","unstructured":"Abuse NIoD. Florida: opioid-involved deaths and related harms National Institute on Drug Abuse Website2020. https:\/\/www.drugabuse.gov\/drug-topics\/opioids\/opioid-summaries-by-state\/florida-opioid-involved-deaths-related-harms"},{"issue":"7","key":"346_CR3","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1093\/cid\/ciaa008","volume":"71","author":"NL McCarthy","year":"2020","unstructured":"McCarthy NL, Baggs J, See I, Reddy SC, Jernigan JA, Gokhale RH, et al. Bacterial infections associated with substance use disorders, large cohort of United States Hospitals, 2012\u20132017. Clin Infect Dis. 2020;71(7):e37\u201344.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"346_CR4","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/cid\/ciw869","volume":"64","author":"MD Morris","year":"2017","unstructured":"Morris MD, Shiboski S, Bruneau J, Hahn JA, Hellard M, Prins M, et al. Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: the InC3 collaboration. Clin Infect Dis. 2017;64(7):860\u20139.","journal-title":"Clin Infect Dis"},{"key":"346_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109428","volume":"234","author":"EW Hall","year":"2022","unstructured":"Hall EW, Rosenberg ES, Jones CM, Asher A, Valverde E, Bradley H. Estimated number of injection-involved drug overdose deaths, United States, 2000\u20132018. Drug Alcohol Depend. 2022;234: 109428.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"346_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/cid\/ciaa823","volume":"72","author":"AE Coye","year":"2021","unstructured":"Coye AE, Bornstein KJ, Bartholomew TS, Li H, Wong S, Janjua NZ, et al. Hospital costs of injection drug use in Florida. Clin Infect Dis. 2021;72(3):499\u2013502.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"346_CR7","first-page":"416","volume":"100","author":"D Coffa","year":"2019","unstructured":"Coffa D, Snyder H. Opioid use disorder: medical treatment options. Am Fam Physician. 2019;100(7):416\u201325.","journal-title":"Am Fam Physician"},{"issue":"1","key":"346_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","volume":"87","author":"J Bell","year":"2020","unstructured":"Bell J, Strang J. Medication treatment of opioid use disorder. Biol Psychiatry. 2020;87(1):82\u20138.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"346_CR9","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/add.15314","volume":"116","author":"LG Hill","year":"2021","unstructured":"Hill LG, Loera LJ, Evoy KE, Renfro ML, Torrez SB, Zagorski CM, et al. Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. Addiction. 2021;116(6):1505\u201311.","journal-title":"Addiction"},{"issue":"1","key":"346_CR10","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1097\/ADM.0000000000000833","volume":"16","author":"S Pham","year":"2021","unstructured":"Pham S, Haigh A, Barrett E. Statewide availability of buprenorphine\/naloxone in acute care hospitals. J Addict Med. 2021;16(1):e48\u201351.","journal-title":"J Addict Med"},{"issue":"1","key":"346_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00952990.2018.1546862","volume":"45","author":"AR Williams","year":"2019","unstructured":"Williams AR, Nunes EV, Bisaga A, Levin FR, Olfson M. Development of a cascade of care for responding to the opioid epidemic. Am J Drug Alcohol Abuse. 2019;45(1):1\u201310.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"346_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/24734306.2020.1869899","volume":"5","author":"A Upadhyaya","year":"2021","unstructured":"Upadhyaya A, Marks LR, Schwarz ES, Liang SY, Durkin MJ, Liss DB. Care cascade for patients with opioid use disorder and serious injection related infections. Toxicol Commun. 2021;5(1):6\u201310.","journal-title":"Toxicol Commun"},{"key":"346_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1475-9276-12-18","volume":"12","author":"JF Levesque","year":"2013","unstructured":"Levesque JF, Harris MF, Russell G. Patient-centred access to health care: conceptualising access at the interface of health systems and populations. Int J Equity Health. 2013;12:18.","journal-title":"Int J Equity Health"},{"issue":"7","key":"346_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5055\/jom.2021.0645","volume":"17","author":"E Kolb","year":"2021","unstructured":"Kolb E, Rueth M. Patient satisfaction with clinic-based medication pick up: addressing pharmacy-level challenges to buprenorphine access. J Opioid Manag. 2021;17(7):77\u201386.","journal-title":"J Opioid Manag"},{"issue":"8","key":"346_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1056\/NEJMp2002908","volume":"383","author":"HLF Cooper","year":"2020","unstructured":"Cooper HLF, Cloud DH, Young AM, Freeman PR. When prescribing isn\u2019t enough\u2014pharmacy-level barriers to buprenorphine access. N Engl J Med. 2020;383(8):703\u20135.","journal-title":"N Engl J Med"},{"key":"346_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108729","volume":"224","author":"NJ Kazerouni","year":"2021","unstructured":"Kazerouni NJ, Irwin AN, Levander XA, Geddes J, Johnston K, Gostanian CJ, et al. Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden. Drug Alcohol Depend. 2021;224: 108729.","journal-title":"Drug Alcohol Depend"},{"key":"346_CR17","doi-asserted-by":"publisher","first-page":"109518","DOI":"10.1016\/j.drugalcdep.2022.109518","volume":"237","author":"LG Hill","year":"2022","unstructured":"Hill LG, Loera LJ, Torrez SB, Puzantian T, Evoy KE, Ventricelli DJ, et al. Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. Drug Alcohol Depend. 2022;237:109518.","journal-title":"Drug Alcohol Depend"},{"key":"346_CR18","doi-asserted-by":"publisher","first-page":"102701","DOI":"10.1016\/j.drugpo.2020.102701","volume":"85","author":"HL Cooper","year":"2020","unstructured":"Cooper HL, Cloud DH, Freeman PR, Fadanelli M, Green T, Van Meter C, et al. Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky. Int J Drug Policy. 2020;85:102701.","journal-title":"Int J Drug Policy"},{"key":"346_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103703","volume":"105","author":"L Textor","year":"2022","unstructured":"Textor L, Ventricelli D, Aronowitz SV. \u201cRed Flags\u201d and \u201cRed Tape\u201d: Telehealth and pharmacy-level barriers to buprenorphine in the United States. Int J Drug Policy. 2022;105: 103703.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"346_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/10826084.2019.1670210","volume":"55","author":"DJ Ventricelli","year":"2020","unstructured":"Ventricelli DJ, Mathis SM, Foster KN, Pack RP, Tudiver F, Hagemeier NE. Communication experiences of DATA-waivered physicians with community pharmacists: a qualitative study. Subst Use Misuse. 2020;55(3):349\u201357.","journal-title":"Subst Use Misuse"},{"key":"346_CR21","unstructured":"Federal Guidelines for Opioid Treatment Programs. 2015."},{"issue":"1","key":"346_CR22","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1097\/ADM.0000000000000833","volume":"16","author":"S Pham","year":"2022","unstructured":"Pham S, Haigh A, Barrett E. Statewide availability of buprenorphine\/naloxone in acute care hospitals. J Addict Med. 2022;16(1):e48\u201351.","journal-title":"J Addict Med"},{"key":"346_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ajem.2021.06.065","volume":"48","author":"A Pourmand","year":"2021","unstructured":"Pourmand A, Beisenova K, Shukur N, Tebo C, Mortimer N, Mazer-Amirshahi M. A practical review of buprenorphine utilization for the emergency physician in the era of decreased prescribing restrictions. Am J Emerg Med. 2021;48:316\u201322.","journal-title":"Am J Emerg Med"},{"key":"346_CR24","unstructured":"Office C. Pharmacies in (Miami-Dade County, Broward County, Palm Beach County), Florida CountyOffice.org: CountyOffice.org. 2022. https:\/\/www.countyoffice.org\/fl-miami-dade-county-pharmacy\/."},{"key":"346_CR25","unstructured":"Directory AH. American Hospital Directory American Hospital Directory Website: American Hospital Directory; 2021. https:\/\/www.ahd.com."},{"issue":"3","key":"346_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/cid\/ciaa823","volume":"72","author":"AE Coye","year":"2020","unstructured":"Coye AE, Bornstein KJ, Bartholomew TS, Hua L, Wong S, Janjua NZ, et al. Hospital costs of injection drug use in Florida. Clin Infect Dis. 2020;72(3):499\u2013502.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"346_CR27","doi-asserted-by":"publisher","first-page":"e1649","DOI":"10.1093\/cid\/ciaa1278","volume":"73","author":"DP Serota","year":"2021","unstructured":"Serota DP, Bartholomew TS, Tookes HE. Evaluating differences in opioid and stimulant use-associated infectious disease hospitalizations in Florida, 2016\u20132017. Clin Infect Dis. 2021;73(7):e1649\u201357.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"346_CR28","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s11606-016-3919-4","volume":"32","author":"CM Velez","year":"2017","unstructured":"Velez CM, Nicolaidis C, Korthuis PT, Englander H. \u201cIt\u2019s been an experience, a life learning experience\u201d: a qualitative study of hospitalized patients with substance use disorders. J Gen Intern Med. 2017;32(3):296\u2013303.","journal-title":"J Gen Intern Med"},{"key":"346_CR29","doi-asserted-by":"publisher","DOI":"10.17226\/25626","volume-title":"National Academies of Sciences, Engineering, and Medicine. Opportunities to improve opioid use disorder and infectious disease services: integrating responses to a dual epidemic","author":"National Academies of Sciences, Engineering, and Medicine","year":"2020","unstructured":"National Academies of Sciences, Engineering, and Medicine. Opportunities to improve opioid use disorder and infectious disease services: integrating responses to a dual epidemic. Washington, DC: The National Academies Press; 2020. https:\/\/doi.org\/10.17226\/25626"},{"issue":"3S","key":"346_CR30","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.japh.2020.01.001","volume":"60","author":"ES Davenport","year":"2020","unstructured":"Davenport ES, Arnett SJ, Nichols MA, Miller ML. Indiana community pharmacist preceptors\u2019 knowledge and perceptions of medication-assisted treatment. J Am Pharm Assoc (2003). 2020;60(3S):S20-S8 e4.","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"4","key":"346_CR31","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/08897077.2019.1616349","volume":"40","author":"A Muzyk","year":"2019","unstructured":"Muzyk A, Smothers ZPW, Collins K, MacEachern M, Wu LT. Pharmacists\u2019 attitudes toward dispensing naloxone and medications for opioid use disorder: a scoping review of the literature. Subst Abus. 2019;40(4):476\u201383.","journal-title":"Subst Abus"},{"issue":"11","key":"346_CR32","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s11606-022-07618-x","volume":"37","author":"H Englander","year":"2022","unstructured":"Englander H, Jones A, Krawczyk N, Patten A, Roberts T, Korthuis PT, et al. A taxonomy of hospital-based addiction care models: a scoping review and key informant interviews. J Gen Intern Med. 2022;37(11):2821\u201333.","journal-title":"J Gen Intern Med"},{"issue":"10","key":"346_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003759","volume":"18","author":"D Lewer","year":"2021","unstructured":"Lewer D, Eastwood B, White M, Brothers TD, McCusker M, Copeland C, et al. Fatal opioid overdoses during and shortly after hospital admissions in England: a case-crossover study. PLoS Med. 2021;18(10): e1003759.","journal-title":"PLoS Med"},{"key":"346_CR34","unstructured":"Bureau USC. Quick facts, population data 2020. https:\/\/www.census.gov\/quickfacts\/fact\/table\/palmbeachcountyflorida,palmbeachtownflorida,palmbeachgardenscityflorida,miamidadecountyflorida\/PST040221."},{"key":"346_CR35","unstructured":"Buprenorphine practitioner locator substance abuse and mental health services administration: substance abuse and mental health services administration; 2021. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/find-treatment\/treatment-practitioner-locator."},{"key":"346_CR36","unstructured":"Administration SAaMHS. Opioid treatment program directory substance abuse and mental health services administration substance abuse and mental health services administration 2021. https:\/\/dpt2.samhsa.gov\/treatment\/."},{"key":"346_CR37","unstructured":"U.S. Department of Health and Human Services OoIG. Geographic disparities affect access to buprenorphine services for opioid use disorder oig.hhs.gov: U.S. Department of Health and Human Services; 2020. https:\/\/oig.hhs.gov\/oei\/reports\/oei-12-17-00240.pdf."},{"key":"346_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2016.03.028","volume":"164","author":"H Hansen","year":"2016","unstructured":"Hansen H, Siegel C, Wanderling J, DiRocco D. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug Alcohol Depend. 2016;164:14\u201321.","journal-title":"Drug Alcohol Depend"},{"issue":"29","key":"346_CR39","doi-asserted-by":"publisher","first-page":"940","DOI":"10.15585\/mmwr.mm7129e2","volume":"71","author":"M Kariisa","year":"2022","unstructured":"Kariisa M, Davis NL, Kumar S, Seth P, Mattson CL, Chowdhury F, et al. Vital signs: drug overdose deaths, by selected sociodemographic and social determinants of health characteristics\u201425 states and the District of Columbia, 2019\u20132020. MMWR Morb Mortal Wkly Rep. 2022;71(29):940\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00346-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-022-00346-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00346-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T10:03:09Z","timestamp":1668765789000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-022-00346-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["346"],"URL":"https:\/\/doi.org\/10.1186\/s13722-022-00346-x","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"assertion":[{"value":"24 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived by the Institutional Review Board of the University of Miami. This study collected no personal information of survey respondents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}